

Reference number(s)
1973-A, 2078-A

## SPECIALTY GUIDELINE MANAGEMENT

### Supprelin LA (histrelin acetate)

#### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### A. FDA-Approved Indication

Supprelin LA is indicated for the treatment of children with central precocious puberty (CPP).

##### B. Compendial Use

1. Gender dysphoria (also known as gender non-conforming or transgender persons)  
**NOTE: Some plans may opt-out of coverage for gender dysphoria.**
2. Preservation of ovarian function
3. Prevention of recurrent menstrual related attacks in acute porphyria

All other indications are considered experimental/investigational and are not a covered benefit.

#### II. CRITERIA FOR INITIAL APPROVAL

##### A. **Central precocious puberty (CPP)**

1. Authorization up to age 12 may be granted for the treatment of CPP in a female member when all of the following criteria are met:
  - a. Intracranial tumor has been evaluated by appropriate lab tests and diagnostic imaging, such as computed tomography (CT scan), magnetic resonance imaging (MRI), or ultrasound.
  - b. The diagnosis of CPP has been confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test or a pubertal level of a third generation luteinizing hormone (LH) assay.
  - c. The assessment of bone age versus chronological age supports the diagnosis of CPP.
  - d. The member was less than 8 years of age at the onset of secondary sexual characteristics.
2. Authorization up to age 13 may be granted for the treatment of CPP in a male member when all of the following criteria are met:
  - a. Intracranial tumor has been evaluated by appropriate lab tests and diagnostic imaging, such as CT scan, MRI, or ultrasound.
  - b. The diagnosis of CPP has been confirmed by a pubertal response to a GnRH agonist test or a pubertal level of a third generation LH assay.
  - c. The assessment of bone age versus chronological age supports the diagnosis of CPP.
  - d. The member was less than 9 years of age at the onset of secondary sexual characteristics.

##### B. **Gender dysphoria**

1. Authorization of 12 months may be granted for pubertal suppression in preparation for gender reassignment in an adolescent member when all of the following criteria are met:
  - a. The member has a diagnosis of gender dysphoria.
  - b. The member has reached Tanner stage 2 of puberty.

Reference number(s)
1973-A, 2078-A

2. Authorization of 12 months may be granted for gender reassignment in an adult member when all of the following criteria are met:
  - a. The member has a diagnosis of gender dysphoria.
  - b. The member will receive Supprelin LA concomitantly with cross sex hormones.

**C. Preservation of ovarian function**

Authorization of 3 months may be granted for preservation of ovarian function when the member is premenopausal and undergoing chemotherapy.

**D. Prevention of recurrent menstrual related attacks in acute porphyria**

Authorization of 12 months may be granted for prevention of recurrent menstrual related attacks in members with acute porphyria when the requested medication is prescribed by or in consultation with a physician experienced in the management of porphyrias.

**III. CONTINUATION OF THERAPY**

**A. Central precocious puberty (CPP)**

1. Authorization up to age 12 may be granted for continuation of therapy for CPP in a female member if the member is currently less than 12 years of age.
2. Authorization up to age 13 may be granted for continuation of therapy for CPP in a male member if the member is currently less than 13 years of age.

**B. Gender Dysphoria**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

**C. All other indications**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

**IV. REFERENCES**

1. Supprelin LA [package insert]. Malvern, PA: Endo Pharmaceuticals Solutions Inc.; May 2017.
2. Kletter GB, Klein KO, Wong YY. A pediatrician's guide to central precocious puberty. *Clin Pediatr*. 2015;54:414-424.
3. Carel J, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics*. 2009;123:e752-e762.
4. Houk CP, Kunselman AR, Lee PA. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. *Pediatrics*. 2009;123:e1059-e1063.
5. Kaplowitz P, Bloch C, the Section on Endocrinology. Evaluation and referral of children with signs of early puberty. *Pediatrics*. 2016;137:e20153732.
6. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2017;102(11):3869–3903.
7. Gender Identity Research and Education Society. Guidance for GPs and other clinicians on the treatment of gender variant people. UK Department of Health. Published March 10, 2008.
8. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, 7th version. ©2012 World Professional Association for Transgender Health. Available at <http://www.wpath.org>.

Reference number(s)
1973-A, 2078-A

9. Moore HCF, Unger JM, Phillips K-A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med*. 2015;372:923-32. doi:10.1056/NEJMoa1413204.
10. Clowse MEB, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. *J Womens Health (Larchmt)*. 2009 Mar; 18(3): 311–319. doi:10.1089/jwh.2008.0857
11. Stein P, Badminton M, Barth J, Rees D, Stewart MF; British and Irish Porphyria Network. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. *Ann Clin Biochem*. 2013 May;50(Pt 3):217-23.
12. Innala, E, Bäckström, T, Bixo, M, Andersson, C. Evaluation of gonadotrophin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. *Acta Obstet Gynecol* 2010;89:95–100.
13. Bangalor Krishna K, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: Update by an international consortium. *Horm Res Paediatr*. 2019 Jul 18:1-16. doi: 10.1159/000501336. [Epub ahead of print]